Alexion pays Achillion a $930m complement
A week after UCB bought Ra to get hold of its complement inhibitor, Alexion takes out Achillion for much the same reason.
UCB goes to Ra for a complementary approach
The $2bn takeout of Ra Pharmaceuticals provides solace for investors bemoaning the biotech market’s poor performance.
Achillion’s first oral Soliris rival hits the buffers
Achillion’s pivot to a next-gen project in paroxysmal nocturnal haemoglobinuria is an admission that its first attempt to compete with Alexion’s Soliris has fallen short.
Upcoming events – Verona waits to exhale and a new test for Alexion
Verona Pharma needs another COPD win, while Alexion seeks a new use for its Soliris successor.
Ra joins the challenge to Alexion’s Soliris stranglehold
Promising data in myasthenia gravis, plus a pledge to compete on price, means that Ra Pharmaceuticals’ zilucoplan could soon give Alexion a headache – and others are…